Literature DB >> 11170441

Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.

B D Lovett1, D Strumberg, I A Blair, S Pang, D A Burden, M D Megonigal, E F Rappaport, T R Rebbeck, N Osheroff, Y G Pommier, C A Felix.   

Abstract

Chromosomal breakage resulting from stabilization of DNA topoisomerase II covalent complexes by epipodophyllotoxins may play a role in the genesis of leukemia-associated MLL gene translocations. We investigated whether etoposide catechol and quinone metabolites can damage the MLL breakpoint cluster region in a DNA topoisomerase II-dependent manner like the parent drug and the nature of the damage. Cleavage of two DNA substrates containing the normal homologues of five MLL intron 6 translocation breakpoints was examined in vitro upon incubation with human DNA topoisomerase IIalpha, ATP, and either etoposide, etoposide catechol, or etoposide quinone. Many of the same cleavage sites were induced by etoposide and by its metabolites, but several unique sites were induced by the metabolites. There was a preference for G(-1) among the unique sites, which differs from the parent drug. Cleavage at most sites was greater and more heat-stable in the presence of the metabolites compared to etoposide. The MLL translocation breakpoints contained within the substrates were near strong and/or stable cleavage sites. The metabolites induced more cleavage than etoposide at the same sites within a 40 bp double-stranded oligonucleotide containing two of the translocation breakpoints, confirming the results at a subset of the sites. Cleavage assays using the same oligonucleotide substrate in which guanines at several positions were replaced with N7-deaza guanines indicated that the N7 position of guanine is important in metabolite-induced cleavage, possibly suggesting N7-guanine alkylation by etoposide quinone. Not only etoposide, but also its metabolites, enhance DNA topoisomerase II cleavage near MLL translocation breakpoints in in vitro assays. It is possible that etoposide metabolites may be relevant to translocations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170441     DOI: 10.1021/bi002361x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  31 in total

Review 1.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

2.  Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.

Authors:  Irina I Vlasova; Wei-Hong Feng; Julie P Goff; Angela Giorgianni; Duc Do; Susanne M Gollin; Dale W Lewis; Valerian E Kagan; Jack C Yalowich
Journal:  Mol Pharmacol       Date:  2010-11-19       Impact factor: 4.436

3.  Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons.

Authors:  Adam C Ketron; Neil Osheroff
Journal:  Phytochem Rev       Date:  2014-03-01       Impact factor: 5.374

4.  Therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  Smita Bhatia
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

5.  Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.

Authors:  Anna M Azarova; Yi Lisa Lyu; Chao-Po Lin; Yuan-Chin Tsai; Johnson Yiu-Nam Lau; James C Wang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

6.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

Review 7.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

8.  Etoposide pathway.

Authors:  Jun Yang; Alessia Bogni; Erin G Schuetz; Mark Ratain; M Eileen Dolan; Howard McLeod; Li Gong; Caroline Thorn; Mary V Relling; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

Review 9.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

10.  In vitro cleavage of the MLL gene by topoisomerase II inhibitor (etoposide) in normal cord and peripheral blood mononuclear cells.

Authors:  Eiichi Ishii; Mariko Eguchi; Minenori Eguchi-Ishimae; Nobuyuki Yoshida; Megumi Oda; Masafumi Zaitsu; Ichiro Fujita; Sumio Miyazaki; Yuhei Hamasaki; Shuki Mizutani
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.